FDA Authorizes Clearance For Kyverna's KYV-101 For Treatment Of Patients With Treatment-Refractory Stiff-Person Syndrome In KYSA-8 Phase 2 Trial

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune disease

KYV-101 is a fully human anti-CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases